- The Pd-catalyzed synthesis of difluoroethyl and difluorovinyl compounds with a chlorodifluoroethyl iodonium salt (CDFI)
-
Herein, we report a simple and efficient method for the direct installation of chlorodifluoroethyl group onto aromatic molecules of various aromatic amides with a new 2-chloro,2,2-difluoroethyl(mesityl)iodonium salt (CDFI). Moreover, the chlorodifluoroeth
- Cao, Chengyao Kimmy,Chen, Chao,Ge, Chenxin,Niu, Yaru,Qu, Hongmei
-
supporting information
(2021/10/01)
-
- INDOL AND INDAZOL DERIVATIVES
-
The present invention relates to indole and indazole derivatives of the following formula (I) wherein A is (AA) and the remaining variables are as defined in the specification. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.
- -
-
Page/Page column 69
(2015/04/15)
-
- COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
-
The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.
- -
-
Page/Page column 91
(2014/06/11)
-
- NAPHTHYLACETIC ACIDS
-
The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.
- -
-
Page/Page column 95-96
(2010/06/15)
-
- N-Cycloalkanoyl-L-phenylalanine derivatives as VCAM/VLA-4 antagonists.
-
A systematic structure-activity relationship investigation of the lead compound 1 resulted the identification of several N-[(substituted alkyl)cycloalkanoyl]-4-[((2,6-dichlorophenyl)carbonyl)amino]-L-phenylalanine derivatives as potent VCAM/VLA-4 antagonists. The data are consistent with a model of these compounds in which these alkanoylphenylalanines reside in a compact gauche (-) bioactive conformation.
- Sidduri, Achyutharao,Tilley, Jefferson W,Hull, Kenneth,Lou, Jian Ping,Kaplan, Gerry,Sheffron, Allen,Chen,Campbell, Robert,Guthrie, Robert,Huang, Tai-Nan,Huby, Nicholas,Rowan, Karen,Schwinge, Virginia,Renzetti, Louis M
-
p. 2475 - 2478
(2007/10/03)
-
- N-alkanoylphenylalanine derivatives
-
Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.
- -
-
-